ABSTRACT
Guillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Although autoantibodies against glycolipids were not detected, immunotherapy with intravenous immunoglobulin and methylprednisolone pulse therapy effectively ameliorated the symptoms. Our report suggests that the COVID-19 vaccine may induce various clinical subtypes of GBS, including a rare variant with sensory ataxia and dysgeusia.
Subject(s)
COVID-19 , Guillain-Barre Syndrome , Ataxia/etiology , BNT162 Vaccine , COVID-19/complications , COVID-19 Vaccines/adverse effects , Dysgeusia/etiology , Guillain-Barre Syndrome/diagnosis , Guillain-Barre Syndrome/drug therapy , Guillain-Barre Syndrome/etiology , Humans , RNA, Messenger , SARS-CoV-2 , VaccinationSubject(s)
Coronavirus Infections/physiopathology , Guillain-Barre Syndrome/physiopathology , Pneumonia, Viral/physiopathology , Adult , Aged , Ageusia/etiology , Asthenia/etiology , Ataxia/etiology , COVID-19 , Coronavirus Infections/complications , Diarrhea/etiology , Facial Paralysis/etiology , Female , Guillain-Barre Syndrome/cerebrospinal fluid , Guillain-Barre Syndrome/complications , Guillain-Barre Syndrome/therapy , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Male , Middle Aged , Myalgia/etiology , Neural Conduction , Olfaction Disorders/etiology , Pandemics , Paraparesis/etiology , Paresthesia/etiology , Pneumonia, Viral/complications , Quadriplegia/etiology , Reflex, Abnormal , Respiratory Insufficiency/etiologySubject(s)
COVID-19 , Opsoclonus-Myoclonus Syndrome , Ataxia/etiology , Female , Humans , Opsoclonus-Myoclonus Syndrome/etiology , SARS-CoV-2Subject(s)
Ataxia , COVID-19 , Gait , Multiple System Atrophy/complications , Ataxia/diagnosis , Ataxia/etiology , Atrophy , Humans , Male , Middle Aged , Multiple System Atrophy/diagnosis , SARS-CoV-2 , Severity of Illness IndexABSTRACT
Opsoclonus-myoclonus-ataxia syndrome is a heterogeneous constellation of symptoms ranging from full combination of these three neurological findings to varying degrees of isolated individual sign. Since the emergence of coronavirus disease 2019 (COVID-19), neurological symptoms, syndromes, and complications associated with this multi-organ viral infection have been reported and the various aspects of neurological involvement are increasingly uncovered. As a neuro-inflammatory disorder, one would expect to observe opsoclonus-myoclonus syndrome after a prevalent viral infection in a pandemic scale, as it has been the case for many other neuro-inflammatory syndromes. We report seven cases of opsoclonus-myoclonus syndrome presumably parainfectious in nature and discuss their phenomenology, their possible pathophysiological relationship to COVID-19, and diagnostic and treatment strategy in each case. Finally, we review the relevant data in the literature regarding the opsoclonus-myoclonus syndrome and possible similar cases associated with COVID-19 and its diagnostic importance for clinicians in various fields of medicine encountering COVID-19 patients and its complications.